Partner - Drug Eluting Coronary Stent System

Mortality due to malaria nearly halved over the last 15 years, due in part to the adoption of artemisinin-based combination therapies (ACT). ACT is comprised of a potent, short-acting artemisinin derivative paired with a longer-acting partner drug. This allows ACT to be administered over just 3 days, but leads to a long terminal phase of partner-drug monotherapy